Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poly-ICLC + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Poly-ICLC + pembrolizumab is an investigational combination therapy consisting of poly-ICLC, a synthetic double-stranded RNA that acts as an immune adjuvant and Toll-like receptor 3 (TLR3) agonist, and pembrolizumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). Poly-ICLC stimulates innate immunity by activating TLR3 and MDA5 pathways, leading to the production of type I interferons and pro-inflammatory cytokines, enhancing dendritic cell maturation and T-cell activation. Pembrolizumab blocks PD-1 on T cells to prevent tumor-induced immune suppression. The combination aims to enhance antitumor immune responses by both stimulating innate immunity (poly-ICLC) and relieving adaptive immune inhibition (pembrolizumab). This regimen has been studied in clinical trials for various cancers including mismatch repair proficient metastatic colon cancer, glioblastoma multiforme (GBM), non-Hodgkin lymphoma, among others[2][7][4].
- Brand names
- KeytrudaHiltonol
- Other names
- pembrolizumab and poly-ICLCMK-3475 and poly-ICLCMK3475 and poly-ICLCMK 3475 and poly-ICLC
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on poly-ICLC + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poly-ICLC + pembrolizumab.